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AbSTRACT
ObJECTIvES The aims of this study were to compile 
a model of a Quality management system (Qms) for 
distribution of medicines, identify the risks in distribution 
to the quality of medicinal products from a maltese 
wholesale dealer’s perspective and evaluate these risks 
using Quality Risk management (QRm) methodology. The 
ultimate objective was to indicate whether risks are being 
well managed and to propose appropriate corrective and 
preventive actions (cAPA).
mEThOD A set of model standard Operating 
Procedures (sOPs) which describe the current wholesale 
dealer’s operations was compiled. These sOPs were 
written in simple English to facilitate comprehensiveness 
by the employees. The various steps in the distribution of 
medicinal products by a wholesaler and the risks in each 
step were identified and a flowchart was compiled. A QRm 
assessment was carried out, taking into consideration 
current risk management activities described in sOPs. no 
further action was recommended for risks which were 
deemed as acceptable, however appropriate cAPA was 
recommended for risks deemed as being unacceptable. 
kEy fINDINgS	 Out	 of	 70	 identified	 risks	 during	
QRm evaluation, 65 risks were deemed acceptable, 
while 5 were deemed not acceptable. Areas exhibiting 
unacceptable risks were ‘Returns of medicinal products’ 
(1 risk) and ‘Temperature monitoring and control during 
shipment from supplier’ (4 risks).
CONCLuSION cAPA was proposed to change 
the profile of unacceptable risks. A model QRm sOP was 
compiled to be used by maltese wholesale dealers in 
setting up a QRm system and to help in fulfilling regulatory 
obligations.
kEyWORDS Quality management system, Quality 
Risk management, standard Operating Procedure, 
corrective and preventive action, medicinal products, 
Wholesale distribution
INTRODuCTION
In an effort to modernise the regulation of pharmaceutical 
technology and quality through international collaboration 
via International conference on harmonisation (Ich), the 
EU has adopted and implemented guidelines to the use 
of Quality Risk management (QRm) in pharmaceutical 
manufacturing.	These	guidelines	available	 in	 ICHQ91 have 
been adopted in Annex 202 of the Eudralex Volume 4 good 
manufacturing (gmP) guidelines. QRm methodology 
has been successfully implemented in pharmaceutical 
manufacturing.
The need for updated good Distribution Practice (gDP) 
guidelines was felt since the gDP guidelines in place have 
been	 published	 in	 1994.3 following consultation with 
stakeholders, the European commission published revised 
GDP	 guidelines	 on	March	 7,	 2013.4 These new guidelines 
direct medicinal product wholesale dealers (mPWD) to start 
implementing a QRm system as per QRm methodology 
already used in the pharmaceutical manufacturing industry 
to improve risk management relating to the quality of 
medicinal products in the legal supply chain.
This study aimed to compile a model Quality 
management system (Qms) for an established mPWD, 
to identify and assess risks and ultimately propose 
appropriate corrective and Preventive Actions (cAPA) for 
unacceptable risks in the distribution chain. This project 
also aimed to compile a model sOP to be used for QRm 
application by a mPWD.
mEThOD
DESIgN Of mODEL QmS
The design of a model Qms for mPWD XyZ Ltd was 
undertaken with the scope of describing the current 
procedures required to ensure that distribution of medicinal 
products is in line with current European and maltese 
legislation and current gDP guidelines. 
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These sOPs were written in simple and concise English and 
aim to list all the procedures carried out by a mPWD for the 
supply of medicinal products and to remain fully compliant 
with	 current	 Maltese/EU	 legislation	 and	 GDP	 guidelines.	
List of compiled sOPs is available in Table 1.
IDENTIfICATION Of RISkS
The main steps involved in the distribution chain from 
when a product is ordered from supplier until delivery to 
an authorised client were identified. steps were classified 
as being within the mPWD’s control or not. Risks within 
each step were identified by asking the question; ‘What 
can go wrong?’
SOP Number Version Name of SOP
01 01 sOP Policies and Procedures
02 01 storage Procedures
03 01 sale and supply Procedures
04 01 Returns and complaints Procedures
05 01 Recalls Procedure
06 01 Internal Audits Procedure
07 01 Verification of supplier and customer status
08 01 Training 
09 01 Purchase and Receipt Procedures
10 01 RP Responsibilities
11 01 change control and Process Deviation Procedures
12 01 cold chain Integrity Procedures for Verified suppliers
13 01 Return	to	Supplier	/	Disposal	of	Pharmaceuticals
14 01 Stock	Taking	and	Expired	/	Damaged	Pharmaceuticals	Handling	Procedure
Table 1	–	A	list	of	compiled	Model	Standard	Operating	Procedures
RISk ANALySIS
failure mode Effects and criticality Analysis (fmE(c)A) was 
chosen as the risk assessment tool since it is recommended 
as	a	main	QRM	tool	by	 ICHQ9	and	Annex	20	of	GMP,	due	
to its wide use in pharmaceutical QRm5,6 and due to its 
relatively ease of use.7
An Excel sheet was compiled with the risk description 
and with current risk management actions according 
to the Qms model. On the basis of risk and current risk 
management actions, a score of 1-5 was assigned for 
each of three factors namely severity (s), probability (P) 
and detectability (D). scores were assigned as follows: 
the higher the severity the higher the score, the higher 
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Figure 1: The various steps involved in the Distribution of Pharmaceuticals
the probability the higher the score and the higher the 
detectability the lower the score. The Risk Probability 
number (RPn) was then calculated per risk by multiplying 
the scores of severity (s), probability (P) and detectability 
(D)	according	to	the	equation:	RPN	=	S	x	P	x	D.		All	details	
were added in an Excel sheet.
RISk ACCEPTAbILITy
According to the developed model, the higher the score 
given for severity and probability, and the lower the score 
given for detectability, the higher the risk. Risks were 
classified into two categories: ‘Acceptable’ risks and ‘not 
acceptable’ risks. The lowest possible RPn mathematically 
is 1, while the highest possible RPn is 125. A risk with an 
RPn above 20 was deemed as not acceptable to ascertain a 
higher degree of safety.
RESuLTS
In total, 16 main steps were identified and a flowchart was 
compiled (figure 1) illustrating the processes involved in 
the flow of medicinal products at a mPWD from supplier 
procurement to final client delivery.
sequence below shows the various processes and procedures applicable to Wholesale distribution 
of pharmaceuticals in malta until final distribution to client. In any of the steps below there are 
risks which might have a bearing on the final quality of pharmaceuticals.
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The two areas which exhibited ‘Non-acceptable’ 
risks were ‘Temperature conditions during 
transit’ and ‘Return of Pharmaceuticals’.
seventy risks were identified and added to the flowchart in 
figure 1. Using fmE(c)A methodology evaluation, 65 risks were 
classified as ‘Acceptable’ (RPn ≤  20) and 5 risks were classified 
as ‘not Acceptable’ (RPn>20). from the ‘not-Acceptable’ 
risks	 (n=5),	 4	were	 related	 to	 temperature	excursions	when	
pharmaceuticals are transported by supplier without 
temperature data-logger and 1 risk is related to acceptance 
of returns from clients without temperature records present.
cAPA was proposed for all unacceptable risks (Table 2).
QuALITy RISk mANAgEmENT SOP
A model wholesale QRm sOP was compiled to facilitate 
re-evaluation of the Qms using QRm methodology by 
the mPWD.
DISCuSSION
mODEL STANDARD OPERATINg 
PROCEDuRES
The model sOPs drafted are based on actual sOPs in use 
by maltese wholesale dealers which in turn are based 
on gDP guidelines. The scope of these procedures is to 
enable the mPWD to have as much control as possible on 
all operations which take place and which can impact the 
quality of medicinal products. some of the procedures 
compiled in this study, which are still very essential for 
the proper functioning of a mPWD go beyond strict gDP 
requirements, for example pharmaceutical waste disposal. 
QRm EXERCISE
The results produced by the fmE(c)A evaluation showed 
that the vast majority of risk factors identified were being 
appropriately managed with current risk management 
actions	 and	 the	 latent	 risk	 is	 acceptable	 (RPN	 =	 or	 <	 20).	
since the model sOPs and operations are modelled around 
real wholesale dealer’s operations rather than being just 
theoretical, this might explain why the majority of RPns 
scored 20 or below. The two areas which exhibited ‘non-
acceptable’ risks were ‘Temperature conditions during 
transit’ and ‘Return of Pharmaceuticals’. These two areas 
have also been identified as being problematic by the 
European commission and the new gDP guidelines aim to 
regulate these areas more thoroughly.
Risk Description RPN 
Score
Risk 
Acceptability
Proposed risk minimisation and / or risk 
management CAPA actions
Temperature excursion during transit for room 
temperature pharmaceuticals (store below 25 °c) 
without data logger in place during winter
30 not 
Acceptable
It is recommended that supplier includes a data 
logger with shipment. This will highly increase 
detectability and this risk can be managed as 
per same risk with data logger.
Temperature excursion during transit for room 
temperature pharmaceuticals (store below 25 °c) 
without data logger in place during summer
60 not 
Acceptable
Temperature excursion during transit for cold-
chain pharmaceuticals (store at 2-8 °c) without 
data logger in place during summer
75 not 
Acceptable
Temperature excursion during transit for cold-
chain pharmaceuticals (store at 2-8 °c) without 
data logger in place during winter
60 not 
Acceptable
Unexpired pharmaceuticals accepted into 
good stock that were kept in unacceptable 
temperature conditions at client
48 not 
Acceptable
It is recommended that unless temperature 
records can be easily accessible and verifiable, 
returns of all pharmaceuticals are not accepted.
Table 2: Description of ‘not Acceptable Risks’ and Proposed cAPA
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Transportation of medicinal products from the EU supplier 
to the maltese wholesale dealer consists of consignments 
that are typically bulkier than orders supplied by the mPWD 
to the individual pharmacy. The shipping time to receive 
such a consignment is also significantly higher than the 
time required by the local mPWD to deliver to an authorised 
client such as a pharmacy. On this basis alone, the risk of 
temperature excursions in consignments in transit to 
malta is higher. It is therefore reasonable to assume that 
more effort to control temperature and detect excursions 
should be necessary for the shipment with higher risk 
rather than the local deliveries. Proposed cAPA is to change 
commercial and technical agreement with suppliers 
to include temperature data loggers in consignments 
shipped to maltese mPWD. The increased detectability will 
decrease the RPn scores to an acceptable level as per risks 
of temperature excursions with data loggers included.
In the current sOP model, returned medicinal products 
(room temperature pharmaceuticals only) are accepted 
provided that the pharmacist signs a form declaring 
appropriate storage. however, one cannot guarantee that 
such storage conditions where kept, since temperature 
records are not verified. It is suggested to amend the sOP 
to refrain from accepting any returns unless verified with 
temperature data that storage conditions at the client have 
been optimal.
QRm IN PRACTICE fOR A mPWD
Various examples and guidance documents were found 
in the literature about the use of QRm in pharmaceutical 
manufacturing. however, no specific information was 
available regarding the implementation of a QRm system 
for a mPWD. This study shows how theoretical guidelines 
and recommendations of risk management as per Annex 20 
and	ICH	Q9	can	be	combined	with	the	real	world	scenario	
resulting in a comprehensive risk assessment taking into 
consideration the risks at each step of the distribution chain 
for the mPWD. The compiled QRm sOP can be adapted by 
a mPWD to evaluate its Qms. such a project needs to be 
constantly updated with new data to truly reflect risks or 
cater for new risks as required. 
This study shows how theoretical guidelines and 
recommendations of risk management as per Annex 20 and ICH 
Q9 can be combined with the real world scenario resulting in 
a comprehensive risk assessment taking into consideration the 
risks at each step of the distribution chain for the MPWD. 
CONCLuSION
When implemented, the Qms and QRm systems developed 
in this study can help the mPWD to ensure that all 
distribution operations are under control and thus be 
in a better position to safeguard the quality of medicinal 
products. Through compliance with legislation and gDP 
guidelines, the mPWD will ensure better patient care 
through the availability of high quality medicinal products.
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